Plan B Backlash Blocks FDA Commissioner Nomination, Take Two
This article was originally published in The Gray Sheet
Executive Summary
FDA will not have a permanent commissioner until a decision is announced on over-the-counter sales of Barr's emergency contraceptive Plan B, if a hold by Senate Democrats is respectedYou may also be interested in...
Von Eschenbach Nomination Still Stalled After Some Movement On Plan B
Senators Hilary Rodham Clinton (D-N.Y.) and Patty Murray (D-Wash.) will maintain their hold on Andrew von Eschenbach's nomination to head FDA, despite what von Eschenbach calls an "important decision" regarding Barr Laboratories' application to offer its Plan B emergency contraceptive over the counter (OTC)
Von Eschenbach Nomination Still Stalled After Some Movement On Plan B
Senators Hilary Rodham Clinton (D-N.Y.) and Patty Murray (D-Wash.) will maintain their hold on Andrew von Eschenbach's nomination to head FDA, despite what von Eschenbach calls an "important decision" regarding Barr Laboratories' application to offer its Plan B emergency contraceptive over the counter (OTC)
Von Eschenbach in ‘07?
Senate HELP Committee staffer says it is "highly unlikely" that Acting FDA Commissioner Andrew von Eschenbach, MD, will be confirmed as permanent commissioner this year. The confirmation hold initiated by Sens. Hillary Rodham Clinton (D-N.Y.) and Patty Murray (D-Wash.) stems from political wrangling over the agency's handling of emergency contraceptive drug, Plan B (1"The Gray Sheet" April 3, 2006, p. 13)...
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Medtech Insight?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: